TRAF3 (TNF Receptor-Associated Factor 3) is a crucial signaling adapter protein that regulates multiple innate immune signaling pathways, including NF-κB, MAPK, and type I interferon responses. It plays dual roles in both promoting and inhibiting inflammation depending on cellular context and stimulus type, making it a key regulator of neuroinflammation in neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis [1].
| Attribute | Value |
|---|---|
| Gene Symbol | TRAF3 |
| Full Name | TNF Receptor-Associated Factor 3 |
| Chromosomal Location | 4p12 |
| NCBI Gene ID | 7188 |
| Ensembl ID | ENSG00000126777 |
| UniProt ID | Q9Y4K0 |
| Gene Type | Protein Coding |
| Aliases | CAP-1, CAP1, RNF83 |
TRAF3 is a member of the TNF receptor-associated factor (TRAF) family of adapter proteins that mediate signaling from the TNF receptor superfamily and Toll-like receptor (TLR) family. The protein contains several functional domains:
TRAF3 regulates multiple critical signaling pathways:
NF-κB Signaling: TRAF3 negatively regulates non-canonical NF-κB signaling by targeting NIK (NF-κB-inducing kinase) for K48-linked ubiquitination and proteasomal degradation. This prevents constitutive activation of the non-canonical NF-κB pathway, which is crucial for controlling inflammatory gene expression in the brain. Loss of TRAF3 leads to NIK accumulation and aberrant NF-κB activation, resulting in heightened inflammatory responses [2].
Type I Interferon Response: TRAF3 is essential for RIG-I-like receptor (RLR)-mediated type I interferon production upon viral infection. It interacts with MAVS (Mitochondrial Antiviral-Signaling protein) to activate IRF3/IRF7-mediated transcription of interferon genes. This antiviral response has implications for understanding viral contributions to neurodegeneration [3].
TLR Signaling: TRAF3 modulates TLR-induced inflammatory responses by interacting with MyD88 and TRIF adaptor proteins. It regulates the balance between pro-inflammatory and anti-inflammatory responses following TLR activation, with context-dependent effects that vary by cell type and stimulus [4].
NLRP3 Inflammasome Regulation: TRAF3 directly interacts with NLRP3 and ASC to suppress inflammasome activation in microglia. This function is particularly relevant in neurodegenerative contexts where inflammasome activation contributes to pathology [5].
TRAF3 is expressed throughout the central nervous system with cell-type-specific patterns:
TRAF3 plays multifaceted roles in Alzheimer's disease pathogenesis:
Amyloid-β Interaction: TRAF3 modulates the inflammatory response to amyloid-β (Aβ) plaques. Loss of TRAF3 function correlates with increased neuroinflammation around plaques. Studies show TRAF3 expression is significantly decreased in AD hippocampus and prefrontal cortex [6].
Tau Pathology: TRAF3 deficiency exacerbates tau pathology-induced neuroinflammation and accelerates cognitive decline in model systems. Restoring TRAF3 expression reduces inflammatory markers and improves neuronal function [1:1].
Therapeutic Targeting: Recent studies explore TRAF3-modulating compounds for AD treatment. Strategies include:
TRAF3 polymorphisms have been associated with PD susceptibility in multiple populations, with particularly significant findings in East Asian cohorts [8]:
α-Synucleinopathy: TRAF3-mediated signaling influences α-synuclein aggregation and dopaminergic neuron viability. Microglial TRAF3 deficiency leads to enhanced neuroinflammation in PD models, accelerating dopaminergic neuron loss [9].
Substantia Nigra: Reduced TRAF3 expression in the substantia nigra pars compacta correlates with disease severity. This may contribute to microglial dysregulation and chronic neuroinflammation characteristic of PD.
LRRK2 Interaction: Studies suggest TRAF3 interacts with LRRK2 signaling pathways, potentially linking genetic and inflammatory factors in PD pathogenesis.
TRAF3 is significantly downregulated in ALS motor cortex and spinal cord:
Motor Neuron Pathology: TRAF3 deficiency exacerbates motor neuron degeneration in ALS models. Loss of TRAF3 in microglia leads to hyperactivated inflammatory responses that harm surviving motor neurons [10].
Astrocyte Dysfunction: Altered TRAF3 expression in astrocytes contributes to non-cell-autonomous toxicity in ALS. Astrocytic TRAF3 deficiency promotes secretion of inflammatory mediators that harm motor neurons.
Therapeutic Potential: Restoring TRAF3 expression in glia represents a potential therapeutic approach for ALS [11].
TRAF3 variants increase susceptibility to herpes simplex encephalitis, demonstrating its critical role in CNS antiviral immunity. This has implications for understanding the proposed link between herpesvirus infection and neurodegeneration [12].
TRAF3 interacts with numerous signaling pathways relevant to neurodegeneration:
TRAF3 Signaling in Neurodegeneration
graph LR
TNF[TNF Family Ligands] --> TRAF3
TLR[TLR Ligands] --> TRAF3
RLR[RLR Viral RNA] --> TRAF3
TRAF3 --> NIK[NIK]
TRAF3 --> MAVS[MAVS]
TRAF3 --> MyD88[MyD88]
NIK --> NFKB[Non-canonical NF-κB]
MAVS --> IRF[IRF3/IRF7]
MyD88 --> TLRNFKB[TLR-induced NF-κB]
NFKB --> INFLAM[Inflammatory Genes]
IRF --> IFN[Type I IFN]
TLRNFKB --> INFLAM2[Inflammatory Genes]
INFLAM --> NEURO[Neurodegeneration]
TRAF3 expression levels in cerebrospinal fluid (CSF) or peripheral blood mononuclear cells may serve as biomarkers for:
Several TRAF3-targeted approaches are in development:
TRAF3 protects against tau pathology-induced neuroinflammation. 2023. ↩︎ ↩︎
Microglial TRAF3 regulates NF-κB and type I interferon signaling in neurodegeneration. 2023. ↩︎
Herpesvirus-induced TRAF3 downregulation contributes to chronic neuroinflammation. 2023. ↩︎
Ubiquitin ligase TRAF3 in TLR signaling and neuroinflammation. 2019. ↩︎
TRAF3 regulates the NLRP3 inflammasome in microglia. 2016. ↩︎
TRAF3 expression in human brain and alterations in neurodegenerative diseases. 2020. ↩︎
Therapeutic targeting of TRAF3 signaling in Alzheimer's disease. 2024. ↩︎
TRAF3 polymorphisms influence Parkinson's disease susceptibility in East Asian populations. 2024. ↩︎
TRAF3-mediated signaling in α-synuclein aggregation and dopaminergic neurodegeneration. 2024. ↩︎
TRAF3 genetic variants and risk for amyotrophic lateral sclerosis. 2022. ↩︎
TRAF3 deficiency exacerbates motor neuron pathology in ALS mouse models. 2021. ↩︎
TRAF3 mutations in herpes simplex encephalitis and implications for neurodegeneration. 2021. ↩︎